Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer

Authors:
  • RCR. L. Capizzi
    R. L. Capizzi
  • LRL. A. Roman
    L. A. Roman
  • STS. Tjulandin
    S. Tjulandin
  • ISI. Smirnova
    I. Smirnova
  • AMA. Manikhas
    A. Manikhas
  • JPJ. S. Paterson
    J. S. Paterson
  • AMA. Major
    A. Major
  • ALA. S. Lundberg
    A. S. Lundberg
  • PFP. Fumoleau
    P. Fumoleau

Abstract
1055 Background: C1311 was designed from mitoxantrone to lessen cardiotoxicity. Although an inhibitor of topo II, its locus of action differs from other topo II inhibitors in that it does not affect the topo II/DNA cleavable complex. Phase I trial dose-limiting toxicity (DLT) was non-cumulative, transient neutropenia without significant nonhematologic toxicity including cardiac function despite prior anthracycline exposure (Isambert et al. Proc. ASCO 2006, Abst 2069). Methods: 53 breast cancer pts resistant to taxanes and anthracyclines and other agents. Median (range) of 3 prior regimens (range 2–6), including median (range) of 6 drugs (range 2–7). Most patients had visceral predominant disease (liver, lung). Initial dose from phase 1 was 480 mg/m2, 1 hr IV infusion on d 1, 8, and 15 of a 28 day cycle. The first 5 patients sustained gr 4 neutropenia (1/5 with febrile neutropenia); starting dose was reduced to 360 mg/m2/wk x 3 q28d for the subsequent 48 patients. Results: A total of 163 cycles of therapy ...